[1] SAKURAI Y,TAKATSUKA H,ONAKA M,et al.Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease[J].Int Arch Allergy Immunol,2014,165(2):111-118. [2] CHEN X,ZHAO Z W,LI L,et al.Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease[J].Lipids Health Dis,2015,14:166. [3] 阳明玉,张明,秦静庭,等.川崎病患儿急性期凝血功能的检测与分析[J].中国感染控制杂志,2009,8(5):346-347. [4] DA LUZ L T,NASCIMENTO B,RIZOLI S.Thrombelastograp hy (TEG®): practical considerations on its clinical use in trauma resuscitation[J].Scand J Trauma Resusc Emerg Med,2013,21:29. [5] LIER H,VORWEG M,HANKE A,et al.Thromboelastome try guided therapy of severe bleeding.Essener Runde algorithm[J].Hamostaseologie,2013,33(1):51-61. [6] 马曙轩,王孟键,张慧敏,等.126例2-14岁儿童血栓弹力图检测结果分析[J].中国输血杂志,2017,30(2):151-153. [7] GROUP J J W.Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)[J].Circ J,2010,74(9): 1989-2020. [8] 李晓惠. 川崎病诊断与治疗新进展[J].中华实用儿科临床杂志,2013,28(1):9-13. [9] 周敏,徐酉华,李晓辉.川崎病血液高凝状态的研究进展[J].国际儿科学杂志,2007,34(3):190-192. [10] 付培培,杜忠东,潘岳松.2002-2010年北京儿童医院川崎病住院患儿临床分析[J].实用儿科临床杂志,2012,27(9):661-664. [11] 刘倩,马曙轩,邱立娟,等.血栓弹力图在儿童川崎病诊治中的应用1例[J].临床输血与检验,2019,21(2): 214-216. [12] ISHIGURO A,ISHIKITA T,SHIMBO T,et al.Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease[J].Thromb Haemost,1998,79(6): 1096-1100. [13] SENZAKI H,KOBAYASHI T,NAGASAKA H,et al.Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy[J].Pediatr Res,2003,53(6):983-988. |